Medication Description: Buserelin (Buserelin)
Synthetic analogue of gonadotropin-releasing factor.
Available in the form of acetate (C 60 H 86 N 16 O 13 · C 2 H 4 O 2 ).
It binds (competitively) to the receptors of the cells of the anterior pituitary and blocks their gonadotropic function: inhibits the secretion of luteinizing and follicle-stimulating hormones, which leads to suppression of the synthesis of sex hormones in the ovaries and seminal vesicles.
Applied with endometriosis, uterine myoma, infertility, as well as hormone-dependent Pak prostate gland.
Assign intranasally and subcutaneously.
When endometriosis is administered intranasally, 0.3 mg 3 times a day, starting from the 1st or 2nd day after the onset of menstruation; treatment duration up to 6 months.
In preparation for the induction of ovulation, 0.2-0.5 mg is administered subcutaneously 1 time per day or intranasally at 0.15-0.3 mg 4 times a day for 1-3 weeks (until the appointment of chorionic gonadotropin), starting with 1st or 21st day of the menstrual cycle.
In the treatment of infertility by in vitro fertilization, it is administered intranasally at 0.15 mg 4 times a day, starting from the middle of the luteal phase of the menstrual cycle (21-24th days of the cycle) until the day when the ovulatory chorionic gonadotropin is administered.
In prostate cancer, subcutaneous injections of 6.6 mg (the contents of the applicator) are administered 1 time per 2 months.
Possible side effects: dyspeptic symptoms, impotence, gynecomastia, allergic reactions, mental disorders (anxiety, insomnia, impaired memory and attention, depression), dizziness, increased blood pressure, dry mucous membranes and skin, impaired liver function, leukopenia, thrombocytopenia, impaired hearing
The drug is contraindicated in pregnancy and lactation.
Forms of release: 0,3% solution for injections in bottles on 1; 3 and 5.5 ml; 0.2% aerosol for intranasal use in vials of 8.5 and 17.5 ml; implant in the form of 2 6.6 mg dosed rods for subcutaneous administration.